

“A Major Milestone” – CEO Hanna Sjöström in interview with Life Science Sweden

Neola Medical takes an important step forward in advancing neonatal care. After years of development, the company has received approval to initiate its first clinical study on preterm born babies—a key step in evaluating its continuous lung monitoring device, Neola®, for this vulnerable patient group. In an interview with Life Science Sweden, CEO Hanna Sjöström discusses the significance of this milestone, what it means for the company, and how it supports Neola Medical’s strategy for entering the U.S. market, where Neola Medical sees significant potential for growth and impact in neonatal care.

Read the full interview here: [Life Science Sweden interview with CEO Hanna Sjöström](#)

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Image Attachments

[A Major Milestone CEO Hanna Sjöström In Interview With Life Science Sweden](#)

Attachments

[“A Major Milestone” – CEO Hanna Sjöström in interview with Life Science Sweden](#)